ArticleFrontiers in immunology2026
HSV-2 gE2/gI2 are immune evasion molecules that bind IgG Fc to inhibit antibody-dependent cellular cytotoxicity.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: HSV-2 glycoproteins C, D, and E (gC2/gD2/gE2) are immunogens included in an experimental HSV-2 vaccine. We evaluated whether these antigens serve as targets for antibody-dependent cellular cytotoxicity (ADCC). Methods: We transiently transfected HEK cells with gC2/gD2/gE2 DNA, added HSV-2 seropositive human convalescent sera (HCS), and measured surface CD107a expression on human NK cells by flow cytometry. Results: We demonstrated that antibodies to gC2/gD2/gE2 mediate ADCC. HSV-2 gE and gI form a complex that binds IgG Fc. We next determined whether gE2/gI2 inhibits ADCC, a crucial function mediated by the IgG Fc, by comparing ADCC titers when HCS were added to cells transfected with gD2, gI2, and a gE2 mutant (gE2 Discussion: We conclude that antibodies to gC2/gD2/gE2 are targets of ADCC, that gE2/gI2 inhibits ADCC, and that an mAb that targets the gE2 IgG Fc binding domain can prevent this inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.